```
$%^STN;HighlightOn=  ***;HighlightOff=***  ;

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAPEZ1617

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  JAN 02  STN pricing information for 2008 now available
 NEWS  3  JAN 16  CAS patent coverage enhanced to include exemplified
                  prophetic substances
 NEWS  4  JAN 28  USPATFULL, USPAT2, and USPATOLD enhanced with new
                  custom IPC display formats
 NEWS  5  JAN 28  MARPAT searching enhanced
 NEWS  6  JAN 28  USGENE now provides USPTO sequence data within 3 days
                  of publication
 NEWS  7  JAN 28  TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS  8  JAN 28  MEDLINE and LMEDLINE reloaded with enhancements
 NEWS  9  FEB 08  STN Express, Version 8.3, now available
 NEWS 10  FEB 20  PCI now available as a replacement to DPCI
 NEWS 11  FEB 25  IFIREF reloaded with enhancements
 NEWS 12  FEB 25  IMSPRODUCT reloaded with enhancements
 NEWS 13  FEB 29  WPINDEX/WPIDS/WPIX enhanced with ECLA and current
                  U.S. National Patent Classification
 NEWS 14  MAR 31  IFICDB, IFIPAT, and IFIUDB enhanced with new custom
                  IPC display formats
 NEWS 15  MAR 31  CAS REGISTRY enhanced with additional experimental
                  spectra
 NEWS 16  MAR 31  CA/CAplus and CASREACT patent number format for U.S.
                  applications updated
 NEWS 17  MAR 31  LPCI now available as a replacement to LDPCI
 NEWS 18  MAR 31  EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 19  APR 04  STN AnaVist, Version 1, to be discontinued
 NEWS 20  APR 15  WPIDS, WPINDEX, and WPIX enhanced with new
                  predefined hit display formats
 NEWS 21  APR 28  EMBASE Controlled Term thesaurus enhanced
 NEWS 22  APR 28  IMSRESEARCH reloaded with enhancements
 NEWS 23  MAY 30  INPAFAMDB now available on STN for patent family
                  searching
 NEWS 24  MAY 30  DGENE, PCTGEN, and USGENE enhanced with new homology
                  sequence search option
 NEWS 25  JUN 06  EPFULL enhanced with 260,000 English abstracts
 NEWS 26  JUN 06  KOREAPAT updated with 41,000 documents
 NEWS 27  JUN 13  USPATFULL and USPAT2 updated with 11-character
                  patent numbers for U.S. applications
 NEWS 28  JUN 19  CAS REGISTRY includes selected substances from
                  web-based collections
```

```
 NEWS 29  JUN 25  CA/CAplus and USPAT databases updated with IPC
                  reclassification data
 NEWS 30  JUN 30  AEROSPACE enhanced with more than 1 million U.S.
                  patent records
 NEWS 31  JUN 30  EMBASE, EMBAL, and LEMBASE updated with additional
                  options to display authors and affiliated
                  organizations
 NEWS 32  JUN 30  STN on the Web enhanced with new STN AnaVist
                  Assistant and BLAST plug-in
 NEWS 33  JUN 30  STN AnaVist enhanced with database content from EPFULL

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:02:52 ON 21 JUL 2008

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 15:03:33 ON 21 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   20 JUL 2008  HIGHEST RN 1035004-20-6
DICTIONARY FILE UPDATES:  20 JUL 2008  HIGHEST RN 1035004-20-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
```

```
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10550381.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
/ Structure 1 in file .gra /


Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 15:04:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        5 TO ITERATE

100.0% PROCESSED         5 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            5 TO      234
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 15:04:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       86 TO ITERATE

100.0% PROCESSED       86 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

L3            1 SEA SSS FUL L1

=> d scan

L3   1 ANSWERS   REGISTRY  COPYRIGHT 2008 ACS on STN
IN   Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-
     quinoxalinyl)methyl]amino]methyl]-
MF   C10 H11 N4 O7 P



/ Structure 2 in file .gra /


**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**
```

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 178.82 | 179.03

FILE 'CAPLUS' ENTERED AT 15:04:49 ON 21 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 21 Jul 2008 VOL 149 ISS 4
FILE LAST UPDATED: 20 Jul 2008 (20080720/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l3
L4 12 L3

=> d ibib abs hitstr

L4 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:529982 CAPLUS <<LOGINID::20080721>>
DOCUMENT NUMBER: 148:487209
TITLE: Combination therapy using an allosteric adenosine A1 receptor enhancer with an opioid analgesic or AMPA/kainate antagonists for the treatment of pain
INVENTOR(S): Eisenach, James Conrad
PATENT ASSIGNEE(S): King Pharmaceuticals Research and Development, Inc., USA
SOURCE: PCT Int. Appl., 54pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |

```
     ---------------     ----    --------    --------------------   --------
     WO 2008051760        A2     20080502    WO 2007-US81598         20071017
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
             GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
             MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
             PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
     US 20080108603       A1     20080508    US 2007-872800          20071016
     US 20080108622       A1     20080508    US 2007-872859          20071016
     US 20080113969       A1     20080515    US 2007-872878          20071016
PRIORITY APPLN. INFO.:                       US 2006-852815P     P   20061019
                                             US 2007-872800      A   20071016
                                             US 2007-872859      A   20071016
                                             US 2007-872878      A   20071016
```

AB The invention provides synergistic combinations for the treatment of conditions assocd. with pain including acute pain, e.g., postoperative pain, chronic pain, inflammatory pain, neuropathic pain and pain assocd. with migraine. In particular, the invention relates to the use of an allosteric adenosine A1 receptor enhancer in conjunction with opioid analgesics or 2-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)/kainate antagonists for alleviating pain, e.g., postoperative pain.

IT ***188696-80-2*** , Becampanel
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(allosteric adenosine A1 receptor enhancer combination with opioid analgesic or AMPA/kainate antagonist for treatment of pain)

RN 188696-80-2 CAPLUS

CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 3 in file .gra /

=> d 1-12 ibib abs hitstr

L4 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:529982 CAPLUS <<LOGINID::20080721>>
DOCUMENT NUMBER: 148:487209
TITLE: Combination therapy using an allosteric adenosine A1 receptor enhancer with an opioid analgesic or AMPA/kainate antagonists for the treatment of pain
INVENTOR(S): Eisenach, James Conrad
PATENT ASSIGNEE(S): King Pharmaceuticals Research and Development, Inc., USA
SOURCE: PCT Int. Appl., 54pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2008051760	A2	20080502	WO 2007-US81598		20071017
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080108603	A1	20080508	US 2007-872800		20071016
US 20080108622	A1	20080508	US 2007-872859		20071016
US 20080113969	A1	20080515	US 2007-872878		20071016
PRIORITY APPLN. INFO.:			US 2006-852815P	P	20061019
			US 2007-872800	A	20071016
			US 2007-872859	A	20071016
			US 2007-872878	A	20071016

AB The invention provides synergistic combinations for the treatment of conditions assocd. with pain including acute pain, e.g., postoperative pain, chronic pain, inflammatory pain, neuropathic pain and pain assocd. with migraine. In particular, the invention relates to the use of an allosteric adenosine A1 receptor enhancer in conjunction with opioid analgesics or 2-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)/kainate antagonists for alleviating pain, e.g., postoperative pain.

IT ***188696-80-2*** , Becampanel
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(allosteric adenosine A1 receptor enhancer combination with opioid analgesic or AMPA/kainate antagonist for treatment of pain)

RN 188696-80-2 CAPLUS

CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 4 in file .gra /

L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2007:908914 CAPLUS <<LOGINID::20080721>>
DOCUMENT NUMBER:	147:355935
TITLE:	Epilepsy
AUTHOR(S):	Knutsen, L. J. S.; Williams, M.
CORPORATE SOURCE:	Worldwide Discovery Research, Cephalon Inc., West Chester, PA, USA
SOURCE:	Comprehensive Medicinal Chemistry II (2006), Volume 6, 279-296. Editor(s): Taylor, John B.; Triggle, David J. Elsevier Ltd.: Oxford, UK. CODEN: 69JQHZ; ISBN: 978-0-08-044513-7
DOCUMENT TYPE:	Conference; General Review

LANGUAGE: English

AB A review on recent developments in diagnosis and treatment of epilepsy. The disease state and disease basis are discussed, along with exptl. disease models, clin. trial issues, current treatments, and unmet medical needs. Emerging research areas are also addressed, including adenosine producing stem cell therapy, novel GABA transporter inhibitors, and .omega. fatty acids.

IT ***188696-80-2*** , Becampanel
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(becampanel has been used for treatment of seizures in patient with epilepsy)

RN 188696-80-2 CAPLUS

CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 5 in file .gra /

REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1111722 CAPLUS <<LOGINID::20080721>>

DOCUMENT NUMBER: 146:74520

TITLE: A microplate solid scintillation counter as a radioactivity detector for high performance liquid chromatography in drug metabolism: Validation and applications

AUTHOR(S): Bruin, Gerard J.; Waldmeier, Felix; Boernsen, K. Olaf; Pfaar, Ulrike; Gross, Gerhard; Zollinger, Markus

CORPORATE SOURCE: Drug Metabolism & Pharmacokinetics, Novartis Pharma AG, Basel, CH-4002, Switz.

SOURCE: Journal of Chromatography, A (2006), 1133(1-2), 184-194
CODEN: JCRAEY; ISSN: 0021-9673

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Sensitive radioactivity detection following high performance liq. chromatog. (HPLC) sepn. remains a challenge in many drug metab. studies with radiolabeled compds. In this work, solid scintillation counting (SSC) after fraction collection into 96-well plates was evaluated as an off-line radioactivity detection method, in comparison with conventional liq. scintillation counting (LSC). The impact of counting time and biol. matrix on the quantification of radiolabeled metabolites and parent drug in samples from animal and human absorption, distribution, metab. and excretion (ADME) studies was investigated. Three different approaches were used to test whether reliable quantification by off-line SSC detection, which requires an approx. const. counting yield during the entire chromatog. run, can be realized: (i) the measurement of radioactivity-spiked biol. blank samples without HPLC sepn. as an extreme case of biol. background, (ii) the measurement of radioactivity-spiked HPLC fractions of biol. blank samples and (iii) the comparison of radio chromatograms obtained by off-line SSC and LSC of real samples from ADME studies with radiolabeled compds. Situations in which variations in SSC yield during an HPLC run are likely to lead to significant errors in

quantitation were identified and are discussed. However, examples from a no. of animal or human ADME studies showed that in the majority of cases off-line SSC provides very similar quant. data, compared with the ref. method of off-line LSC radioactivity detection. Approaches for validation of the off-line SSC approach in crit. cases are discussed. The main advantages of off-line SSC, compared with off-line LSC, are lower detection limits and a substantially higher throughput. Several applications of off-line SSC detection in ADME studies are shown.

IT ***188696-80-2*** , Amp397
RL: ANT (Analyte); ANST (Analytical study)
(microplate solid scintillation counter combined with HPLC for high throughput drug metab. screening)

RN 188696-80-2 CAPLUS

CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 6 in file .gra /

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:395110 CAPLUS <<LOGINID::20080721>>

DOCUMENT NUMBER: 142:435803

TITLE: Combinations comprising AMPA receptor antagonists for the treatment of neuropathic pain

INVENTOR(S): Karolchyk, Mary Ann; Lingenhoehl, Kurt; Ofner, Silvio; Fox, Alyson

PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH

SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005039593	A1	20050506	WO 2004-EP11870	20041020
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: GB 2003-24542 A 20031021

OTHER SOURCE(S): MARPAT 142:435803

AB The present invention relates to combinations suitable for the treatment of pain, esp. neuropathic pain. The combinations comprise at least 1 AMPA receptor antagonist and at least one combination partner selected from the group consisting of cyclooxygenase inhibitors, vanilloid receptor

antagonists, opioids, tricyclic antidepressants, anticonvulsants, cathepsin S inhibitors and GABAB receptor agonists. {[(7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl)amino]methyl}phosphonic acid may be administered to a patient in a total daily dosage of 60-400 mg.

IT ***188696-80-2***

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations comprising AMPA receptor antagonists for the treatment of neuropathic pain)

RN 188696-80-2 CAPLUS

CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 7 in file .gra /

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:995976 CAPLUS <<LOGINID::20080721>>

DOCUMENT NUMBER: 141:406122

TITLE: Use of substituted aminoalkanephosphonic acids in the treatment of multiple sclerosis and related demyelinating diseases

INVENTOR(S): Foster, Carolyn Ann; Hiestand, Peter C.; Lingenhoehl, Kurt

PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma GmbH

SOURCE: PCT Int. Appl., 11 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004098603	A1	20041118	WO 2004-EP5043	20040511
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: GB 2003-10868 A 20030512

OTHER SOURCE(S): MARPAT 141:406122

AB The present invention relates to a new pharmaceutical use of substituted aminoalkanephosphonic acids, esp. multiple sclerosis and related demyelinating diseases.

IT ***188696-80-2***

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(aminoalkanephosphonic acids for treatment of multiple sclerosis and related demyelinating diseases)

RN 188696-80-2 CAPLUS

CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 8 in file .gra /

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:857406 CAPLUS <<LOGINID::20080721>>

DOCUMENT NUMBER: 141:325767

TITLE: Combinations of antiepileptic drugs for the treatment of neurological disorders

INVENTOR(S): Aitken, David; Lingenhohl, Kurt; Schmutz, Markus

PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma GmbH

SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087161	A1	20041014	WO 2004-EP3518	20040402
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004226825	A1	20041014	AU 2004-226825	20040402
AU 2004226825	B2	20070816		
CA 2521274	A1	20041014	CA 2004-2521274	20040402
EP 1620103	A1	20060201	EP 2004-725366	20040402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009170	A	20060411	BR 2004-9170	20040402
CN 1767832	A	20060503	CN 2004-80009218	20040402
JP 2006522062	T	20060928	JP 2006-504970	20040402
US 20060194766	A1	20060831	US 2005-550381	20050921
IN 2005CN02527	A	20070831	IN 2005-CN2527	20051004
PRIORITY APPLN. INFO.:			GB 2003-7860 A	20030404
			WO 2004-EP3518 W	20040402

OTHER SOURCE(S): MARPAT 141:325767

AB The invention discloses combinations comprising two antiepileptics, pharmaceutical compns. comprising such combinations, and the use of such combinations for the prepn. of a medicament for the treatment of neurol.

disorders, esp. epilepsy.
IT ***188696-80-2***
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiepileptic drug combination for treatment of neurol. disorder)
RN 188696-80-2 CAPLUS
CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 9 in file .gra /

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:892622 CAPLUS <<LOGINID::20080721>>
DOCUMENT NUMBER: 139:358798
TITLE: New uses of substituted aminoalkanephosphonic acids
INVENTOR(S): Lingenhoehl, Kurt; Auberson, Yves; Fox, Alyson; Neijt, Hans C.; Kalkman, Hans O.
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003092701	A2	20031113	WO 2003-EP4466	20030429
WO 2003092701	A3	20040408		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2482524	A1	20031113	CA 2003-2482524	20030429
AU 2003232224	A1	20031117	AU 2003-232224	20030429
EP 1501518	A2	20050202	EP 2003-747434	20030429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009611	A	20050209	BR 2003-9611	20030429
CN 1649599	A	20050803	CN 2003-809597	20030429
JP 2005527600	T	20050915	JP 2004-500885	20030429
ZA 2004007642	A	20060628	ZA 2004-7642	20040922
MX 2004PA10816	A	20050307	MX 2004-PA10816	20041029
US 20060293282	A1	20061228	US 2004-512923	20041029
NO 2004005089	A	20041123	NO 2004-5089	20041123
PRIORITY APPLN. INFO.:			GB 2002-9886 A	20020430
			GB 2002-9887 A	20020430
			GB 2002-9889 A	20020430
			GB 2002-10371 A	20020507

	GB 2002-12760	A	20020531
	WO 2003-EP4466	W	20030429
	WO 2003-US4466	W	20030429

OTHER SOURCE(S): MARPAT 139:358798

AB The present invention relates the use of substituted aminoalkanephosphonic acids in treating neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders.

IT ***188696-80-2***
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted aminoalkanephosphonic acids for treatment of mental disorders and nervous system disorders)

RN 188696-80-2 CAPLUS

CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 10 in file .gra /

L4 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2002:512328 CAPLUS <<LOGINID::20080721>>
DOCUMENT NUMBER:	138:147543
TITLE:	Genotoxicity assessment of the antiepileptic drug AMP397, an Ames-positive aromatic nitro compound
AUTHOR(S):	Suter, Willi; Hartmann, Andreas; Poetter, Franziska; Sagelsdorff, Peter; Hoffmann, Peter; Martus, Hans-Jorg
CORPORATE SOURCE:	Toxicology/Pathology, Novartis Pharma AG, Basel, 4002, Switz.
SOURCE:	Mutation Research, Genetic Toxicology and Environmental Mutagenesis (2002), 518(2), 181-194 CODEN: MRGMFI; ISSN: 1383-5718
PUBLISHER:	Elsevier B.V.
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB AMP397 is a novel antiepileptic agent and the first competitive AMPA antagonist with high receptor affinity, good in vivo potency, and oral activity. AMP397 has a structural alert (arom. nitro group) and was mutagenic in Salmonella typhimurium strains TA97a, TA98 and TA100 without S9, but neg. in the nitroreductase-deficient strains TA98NR and TA100NR. The amino deriv. of AMP397 was neg. in wild-type strains TA98 and TA100. AMP397 was neg. in a mouse lymphoma tk assay, which included a 24 h treatment without S9. A weak micronucleus induction in vitro was found at the highest concns. tested in V79 cells with S9. AMP397 was neg. in the following in vivo studies, which included the max. tolerated doses of 320 mg/kg in mice and 2000 mg/kg in rats: Muta Mouse assay in colon and liver (5.times.320 mg/kg) at three sampling times (3, 7 and 31 days after the last administration); DNA binding study in the liver of mice and rats after a single treatment with [14C]-AMP397; comet assay (1.times.2000 mg/kg) in jejunum and liver of rats, sampling times 3 and 24 h after administration; micronucleus test (2.times.320 mg/kg) in the bone marrow of mice, sampling 24 h after the second administration. Based on these results, it was concluded that AMP397 has no genotoxic potential in vivo. In particular, no genotoxic metabolite is formed in mammalian cells, and, if formed by intestinal bacteria, is unable to exert any genotoxic activity in the adjacent intestinal tissue. These data were considered to provide sufficient safety to initiate clin. development of the compd.

IT ***188696-80-2*** , AMP 397
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(genotoxicity assessment of antiepileptic drug AMP397, an Ames-pos. arom. nitro compd.)
RN 188696-80-2 CAPLUS
CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 11 in file .gra /

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:222645 CAPLUS <<LOGINID::20080721>>
DOCUMENT NUMBER: 137:257504
TITLE: N-phosphonoalkyl-5-aminomethylquinoxaline-2,3-diones: In vivo active AMPA and NMDA (glycine) antagonists
AUTHOR(S): Auberson, Yves P.; Acklin, Pierre; Bischoff, Serge; Moretti, Robert; Ofner, Silvio; Schmutz, Markus; Veenstra, Siem J.
CORPORATE SOURCE: Novartis Pharma AG, Basel, 4002, Switz.
SOURCE: Biomedical and Health Research (2001), 45(Excitatory Amino Acids: Ten Years Later), 37-42
CODEN: BIHREN; ISSN: 0929-6743
PUBLISHER: IOS Press
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:257504
AB N-Substituted 5-aminomethylquinoxalinediones contg. carboxy or phosphonic acids yield potent and selective AMPA and/or NMDA (glycine-binding site) antagonists. Phosphonic acid derivs. are particularly water-sol. and display potent anticonvulsant effects in the electroshock-induced convulsion assay in mice.
IT ***188696-80-2P***
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-phosphonoalkyl-5-aminomethylquinoxaline-2,3-diones and activity as in vivo active AMPA and NMDA (glycine) antagonists and anticonvulsants)
RN 188696-80-2 CAPLUS
CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 12 in file .gra /

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:118530 CAPLUS <<LOGINID::20080721>>
DOCUMENT NUMBER: 130:306031
TITLE: N-Phosphonoalkyl-5-aminomethylquinoxaline-2,3-diones: in vivo active AMPA and NMDA(glycine) antagonists

AUTHOR(S): Auberson, Yves P.; Acklin, Pierre; Bischoff, Serge; Moretti, Robert; Ofner, Silvio; Schmutz, Markus; Veenstra, Siem J.
CORPORATE SOURCE: Novartis Pharma AG, Basel, 4002, Switz.
SOURCE: Bioorganic & Medicinal Chemistry Letters (1999), 9(2), 249-254
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB N-Substituted 5-aminomethylquinoxalinediones contg. carboxy or phosphonic acids yield potent and selective AMPA and/or NMDA (glycine-binding site) antagonists. Phosphonic acid derivs. are particularly water-sol. and display potent anticonvulsant effects in the electroshock-induced convulsion assay in mice.

IT ***188696-80-2P***
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phosphonoalkyl aminomethylquinoxalinediones as in vivo active AMPA and NMDA(glycine) antagonists, and prepn., receptor binding, and anticonvulsant activity)

RN 188696-80-2 CAPLUS
CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 13 in file .gra /

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:268508 CAPLUS <<LOGINID::20080721>>
DOCUMENT NUMBER: 128:321753
ORIGINAL REFERENCE NO.: 128:63785a,63788a
TITLE: Substituted aminoalkane phosphonic acids
INVENTOR(S): Acklin, Pierre; Allgeier, Hans; Auberson, Yves; Ofner, Silvio; Veenstra, Siem Jacob
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Acklin, Pierre; Allgeier, Hans; Auberson, Yves; Ofner, Silvio; Veenstra, Siem Jacob
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817672	A1	19980430	WO 1997-EP5843	19971022

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW

```
        RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
            GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
            GN, ML, MR, NE, SN, TD, TG
     CA 2269807          A1   19980430    CA 1997-2269807        19971022
     CA 2269807          C    20070410
     AU 9851885          A    19980515    AU 1998-51885          19971022
     EP 934326           A1   19990811    EP 1997-946755         19971022
     EP 934326           B1   20060503
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, FI, RO
     CN 1234037          A    19991103    CN 1997-199101         19971022
     CN 1092202          B    20021009
     BR 9713489          A    20000229    BR 1997-13489          19971022
     JP 2001502681       T    20010227    JP 1998-518970         19971022
     JP 3908790          B2   20070425
     HU 2000000383       A2   20010528    HU 2000-383            19971022
     HU 2000000383       A3   20030128
     RU 2181362          C2   20020420    RU 1999-110376         19971022
     IL 129394           A    20020523    IL 1997-129394         19971022
     SK 282548           B6   20021008    SK 1999-523            19971022
     AT 325128           T    20060615    AT 1997-946755         19971022
     PT 934326           T    20060831    PT 1997-946755         19971022
     PL 192286           B1   20060929    PL 1997-332775         19971022
     ES 2264171          T3   20061216    ES 1997-946755         19971022
     NO 9901902          A    19990621    NO 1999-1902           19990421
     KR 2000052747       A    20000825    KR 1999-703547         19990423
     US 6117873          A    20000912    US 1999-297010         19990423
PRIORITY APPLN. INFO.:                   CH 1996-2621        A  19961024
                                         WO 1997-EP5843      W  19971022
OTHER SOURCE(S):         MARPAT 128:321753
GI


/ Structure 14 in file .gra /


AB   The prepn. of title compds. I (R1 = OH, aliph., araliph. or arom. radical;
     X = bivalent aliph., cycloaliph., cycloaliph.-aliph., araliph.,
     heteroarylaliph. or arom. radical; R2 = H or an aliph. or araliph.
     radical; alk = lower alkylidene; R3, R4, R5 = independently represent H,
     lower alkyl, halogen, trifluoromethyl, cyano or nitro) is described.  I
     and their salts may be used for treating pathol. conditions which respond
     to the blocking of exciter amino acid receptors, and for producing
     pharmaceutical compns.
IT     ***188696-80-2P***
     RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
     study); PREP (Preparation); USES (Uses)
        (prepn. of substituted aminoalkane phosphonic acids as amino acid
        receptors)
RN   188696-80-2  CAPLUS
CN   Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-
     quinoxalinyl)methyl]amino]methyl]-  (CA INDEX NAME)


/ Structure 15 in file .gra /

REFERENCE COUNT:         3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
```

L4 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:278950 CAPLUS <<LOGINID::20080721>>
DOCUMENT NUMBER: 126:251169
ORIGINAL REFERENCE NO.: 126:48567a,48570a
TITLE: Preparation of novel 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives as AMPA, kainate and/or glycine binding sites of the NMDA receptor ligands
INVENTOR(S): Acklin, Pierre; Allgeier, Hans; Auberson, Yves; Biollaz, Michel; Moretti, Robert; Ofner, Silvio; Veenstra, Siem Jacob
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Acklin, Pierre; Allgeier, Hans; Auberson, Yves; Biollaz, Michel; Moretti, Robert; Ofner, Silvio; Veenstra, Siem Jacob
SOURCE: PCT Int. Appl., 157 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9708155	A1	19970306	WO 1996-EP3644	19960819
W: AL, AU, BB, BG, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2227851	A1	19970306	CA 1996-2227851	19960819
AU 9668742	A	19970319	AU 1996-68742	19960819
AU 705871	B2	19990603		
EP 853617	A1	19980722	EP 1996-929275	19960819
EP 853617	B1	20040303		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI				
CN 1193968	A	19980923	CN 1996-196581	19960819
HU 9801676	A2	19990329	HU 1998-1676	19960819
HU 9801676	A3	19990428		
JP 11511444	T	19991005	JP 1997-509801	19960819
JP 3159711	B2	20010423		
IL 122987	A	20010808	IL 1996-122987	19960819
AT 260902	T	20040315	AT 1996-929275	19960819
PT 853617	T	20040630	PT 1996-929275	19960819
ES 2217324	T3	20041101	ES 1996-929275	19960819
PL 189637	B1	20050930	PL 1996-324992	19960819
TW 438782	B	20010607	TW 1996-85110230	19960822
IN 1996MA01489	A	20071026	IN 1996-MA1489	19960823
ZA 9607322	A	19970228	ZA 1996-7322	19960829
NO 9800814	A	19980421	NO 1998-814	19980226
NO 310236	B1	20010611		
US 6080743	A	20000627	US 1998-29525	19980227
HK 1010196	A1	20050121	HK 1998-111287	19981016

PRIORITY APPLN. INFO.: CH 1995-2479 A 19950831
CH 1995-2734 A 19950927

CH 1995-2747	A	19950928
CH 1996-1213	A	19960510
CH 1996-1630	A	19960628
CH 1996-1214	A	19960510
WO 1996-EP3644	W	19960819

OTHER SOURCE(S): MARPAT 126:251169
GI

/ Structure 16 in file .gra /

AB The title compds. [I; one of R1 and R2 = R5 and the other = CH(R6)-alk-R7, alk-CH(R6)R7, etc. (wherein R5 = R3, R4; R6 = unsubstituted or lower alkylated and/or lower alkanoylated amino; R7 = H, an aliph., cycloaliph., heterocycloaliph. radical, etc.); R3, R4 = H, lower alkyl, halo, etc.], useful in the prepn. of a medicament for the treatment of pathol. conditions that are responsive to blocking of AMPA, kainate and/or glycine binding sites of the NMDA receptor, were prepd. and formulated. Thus, reaction of 7-bromo-5-bromomethyl-2,3-dimethoxyquinoxaline with glycine tert-Bu ester hydrochloride in the presence of Et3N in MeCN followed by deesterification afforded the title compd. II.HBr. Compds. I are effective at 10-500 mg/day when administered orally to 75 kg patient.

IT ***188696-80-2P***
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of novel 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivs. as AMPA, kainate and/or glycine binding sites of the NMDA receptor ligands)

RN 188696-80-2 CAPLUS

CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 17 in file .gra /

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	71.33	250.36
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-10.40	-10.40

STN INTERNATIONAL LOGOFF AT 15:05:35 ON 21 JUL 2008